CYNTHIA REPELLA: Open Payments
NPI 1578624532 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,759 in 60 payments from 16 companies in 2025. Trend: 2023 $670 · 2024 $953 · 2025 $1,759
Food & beverage: $1,490Education: $223Consulting: $46
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $351 |
| AstraZeneca Pharmaceuticals LP | 5 | $218 |
| Novartis Pharmaceuticals Corporation | 7 | $146 |
| GlaxoSmithKline, LLC. | 7 | $143 |
| Lilly USA, LLC | 3 | $127 |
| SANOFI-AVENTIS U.S. LLC | 1 | $90 |
| Pharming Healthcare, Inc. | 3 | $77 |
| ADMA BioManufacturing LLC | 2 | $46 |
| GENZYME CORPORATION | 1 | $38 |
Products named: DUPIXENT, CUVITRU, EBGLYSS, NUCALA, TEZSPIRE, AIRSUPRA, RUCONEST, EOHILIA.
Industry payments across NV — which companies pay providers there.
